Original Contributions |
From the Departments of Medicine (J.S.K., R.R.B., J.W., T.J.A., J.S.) and Radiology (L.M.B.), Royal Postgraduate Medical School, Hammersmith Hospital, London; the Institute of Biochemistry (C.J.P.), Royal Infirmary, Glasgow; the Wynn Institute for Metabolic Research (D.C.), London; and the Department of Medicine (S.P.), St Mary's Hospital Medical School, London, UK.
Correspondence to J.S. Kooner, MD, FRCP, Consultant Cardiologist/Senior Lecturer, National Heart and Lung Institute, Imperial College School of Medicine, Hammersmith Hospital, Du Cane Rd, London W12 0NN, UK.
| Abstract |
|---|
|
|
|---|
Key Words: myocardial infarction abdominal obesity nonesterified fatty acids insulin resistance
| Introduction |
|---|
|
|
|---|
| Methods |
|---|
|
|
|---|
Diagnosis of MI and angiographic coronary disease was made before the age of 50 years. Patients were not studied within 3 months of an MI or coronary intervention. Patients with fasting blood glucose values >6.7 mmol/L, previous history of noninsulin-dependent diabetes mellitus (NIDDM), insulin-dependent-diabetes mellitus (IDDM), hypertension, dyslipidemia (cholesterol levels >8.0 mmol/L and triglycerides >4 mmol/L), abnormal liver or thyroid function tests, and a BMI >30.0 kg/m2 were excluded. Treatment with ß-blockers (6 PSMIs and 5 BWMIs) and angiotensin-converting enzyme inhibitors (3 PSMIs and 4 BWMIs) was stopped 2 weeks before the study. The remaining subjects were not taking ß-blockers, thiazide diuretics, or other drugs affecting lipid or carbohydrate metabolism. Specific dietary counseling or coronary rehabilitation was not undertaken after the acute event or prior to the study in MI patients. Control subjects were healthy male volunteers randomly selected from three general practitioners' lists and had no previous history of cardiovascular disease or diabetes. All had a normal resting electrocardiogram and a normal exercise electrocardiogram at high work load. Control subjects were matched as a group to patients with MI with respect to ethnic origin, age, weight, and BMI. None were taking any medication. The Sikhs were residents of the United Kingdom for a mean of 22 years (range, 8 to 34).
Thirty-seven first-degree relatives of five PSMIs (20 men and 17 women; mean±SD age, 36±13 years) were also studied to investigate familial aggregation of defective insulin action. Relatives with a previous history of CHD, NIDDM, IDDM, hypertension, major organ disease, or a BMI >30 kg/m2 were excluded. All subjects gave informed consent before participating in the study.
Medical history and physical activity (leisure time) were assessed by interview. The physical activity score, based on the frequency, duration, and intensity of exercise undertaken in the 4 weeks prior to the study, was calculated for each individual (as the best approximate available), and energy expenditure was calculated according to published data.12 Blood pressure was measured with a random-zero sphygmomanometer (Hawksley and Sons) after a 10-minute rest and with the subject in the sitting position. Systolic and diastolic blood pressures were measured at the time of the first and fifth Korotkoff sounds, respectively. Waist and hip girths were measured in the standing position with a fiberglass tape. Waist was measured as the smallest horizontal girth between the costal margin and the iliac crests and the hip as the circumference at the level of the greater trochanters. The study protocol was approved by the hospital ethics committee.
Experimental Protocol
The association of insulin action with MI was tested in 17
MI patients (8 PSMIs and 9 BWMIs) and 17 control subjects (9 PSCs and 8
BWCs) by using the
hyperinsulinemic-euglycemic clamp.
Assessment of metabolic factors associated with insulin
resistance was also investigated in 51 MI patients (24 PSMIs and 27
BWMIs) and 53 matched, male control subjects (28 PSCs and 25 BWs) after
ingestion of an oral glucose load. Metabolic factors
associated with insulin resistance and showing significant differences
between PSMI patients and PSCs were measured in 37 first-degree
relatives of 5 PSMI patients. All studies were performed after an
overnight fast (12 hours).
Hyperinsulinemic-Euglycemic Clamp
Insulin sensitivity was assessed by the
hyperinsulinemic-euglycemic clamp technique
in 17 MI patients (8 PSMIs and 9 BWMIs) and 17 control subjects (9 PSCs
and 8 BWCs).13 Two polyethylene cannulas were
inserted, one into an antecubital vein (for infusion of 20% glucose)
and the second retrogradely into the contralateral wrist vein, which
was placed in a heated (65°C) box for sampling of
arterial blood. After baseline blood samples were taken, a
constant infusion of short-acting human insulin (Actrapid, Novo
Industry) was administered at a rate of 0.05 U ·
kg-1 · h-1. Plasma
glucose concentration was determined at 5-minute intervals by using a
Yellow Springs glucose analyzer, and the infusion of 20%
glucose was adjusted to maintain a constant plasma glucose
concentration of 4.0 mmol/L for 210 minutes. Glucose infusion
rates corrected for the steady-state glucose concentration are
expressed in micromoles per kilogram per minute per millimole per
liter.
OGTT
Fifty-one MI patients (24 PSMIs and 27 BWMIs), 53 matched, male
control subjects (28 PSCs and 25 BWCs), and 37 first-degree relatives
of 5 PSMI patients were given a 75-g oral glucose load. Venous blood
was taken in the fasting state and at 60 and 120 minutes during the
OGTT for determination of glucose, insulin, lipid, and NEFA levels.
Samples were stored on ice. Plasma was separated within 10 minutes and
stored at -70°C until analysis.
Dual-Energy X-Ray Absorptiometry (DXA)
Body composition was measured by DXA scan (Lunar DPX-L scanner,
Lunar Radiation Corp). This method has very high precision and accuracy
for measurement of total body and regional fat.14
Abdominal fat mass, measured between the costal margins and iliac
crest, was assessed as a percentage of total fat mass.
Biochemical and Hemostatic Assays
Blood glucose was measured by the glucose oxidase method
on a Yellow Springs glucose analyzer. Plasma insulin was
measured by an immunoradiometric assay.15 The
interassay coefficient of variation was 10%. Serum NEFAs were measured
by enzymatic assay (NEFA C, Wako Chemicals GmbH). Serum
cholesterol and triglycerides were
analyzed by automated enzymatic methods (C-System,
Boehringer Mannheim). Lipoprotein(a) was measured by an ELISA
(Biopool AB). PAI-1 was measured as described
previously.16 Small-LDL particle size (LDL-III)
was measured on fresh plasma by density gradient
ultracentrifugation by the method of Griffin et
al.17 In brief, fresh plasma (with EDTA, 1 g/L)
was subfractionated by discontinuous, nonequilibrium density gradient
centrifugation in an SW-40 swing-out rotor (Beckman)
using a six-step salt gradient. After 24 hours of
centrifugation (40 000 rpm, 23°C) the LDL
subfractions were eluted from the centrifuge tube by upward
displacement through a spectrophotometer and continuously monitored at
280 nm. LDL subfractions were calculated by proportioning the total
mass (lipid and protein) of sequentially isolated LDL
(d=1.019 to 1.063 g/mL) on the basis of the areas beneath
the elution profile after correction for differences in extinction
coefficients at 280 nm. The reproducibility of this fractionation
procedure was assessed by replicate analysis of plasma from a
single individual. The within-batch (n=6x1 rotor) coefficient of
variation for LDL-III isolated by this procedure was <5.4%. The
between-batch variation (n=6x2 rotors) for the same subfractions was
<6.5%.
Statistical Analysis
Statistical analysis was performed with the SPSS
program (SPSS Inc). The logarithms of variables were used in the
statistical analysis to normalize the distributions.
Comparisons were performed separately between PSMI patients and PSCs
and between BWMI patients and BWCs by ANOVA. The study was not designed
to compare differences between the two ethnic groups. Sheffè's
test was used when the overall F statistic was significant. All data
are expressed as mean and SEM. P<.05 was considered
statistically significant.
| Results |
|---|
|
|
|---|
|
Insulin-mediated suppression of NEFAs was impaired in PSMI patients compared with PSCs (for PSMIs at 0 to 30 minutes, 0.63±0.04 to 0.15±0.03 mEq/L versus PSCs at 0 to 30 minutes, 0.45±0.07 to 0.07±0.02 mEq/L, P<.05). There were no differences in insulin-mediated suppression of NEFAs in BWMI patients compared with BWCs (for BWMIs at 0 to 30 minutes, 0.43±0.03 to 0.08±0.05 mEq/L versus BWCs at 0 to 30 minutes, 0.54±0.07 to 0.12±0.02 mEq/L, P=NS). Abdominal fat as a percentage of total body fat was greater in MI patients compared with their respective ethnic control subjects (for PS, 38.7±1.8% versus 30.4±1.6% and for BW, 35.0±2.5% versus 28.9±1.8%, both P<.05).
Among patients undergoing the hyperinsulinemic-euglycemic clamp study, fasting cholesterol, HDL cholesterol and its subfractions, triglyceride, LDL mass, and lipoprotein(a) were similar in MI patients and control subjects. However, apolipoprotein B, small dense LDL (as a percentage of total LDL mass), and PAI-1 were higher in BWMI patients than in BWCs (101±8 versus 81±4 mg/dL, 41±9% versus 22±6%, and 14.3±3.0 versus 8.3±1.2 IU/mL, respectively, all P<.05) but not in PSMI patients compared with PSCs (88±5 versus 79±2 mg/dL, 19±6% versus 44±11%, and 8.9±1.7 versus 8.0±1.6 IU/mL, respectively).
OGTT
Fasting blood glucose was <6.7 mmol/L in all subjects.
Fasting plasma insulin was higher in MI patients from both ethnic
groups than in their respective control subjects. Among PSs, 5 of the
24 MI patients had impaired glucose tolerance (2-hour glucose levels of
11.0, 11.1, 10.0, 11.3, and 11.7 mmol/L), 3 of the 24 MI patients
had diabetes (2-hours glucose levels of 12.5, 12.1, and 12.8
mmol/L), and 1 of the 28 control subjects had diabetes (2-hour glucose
level of 11.9 mmol/L).18 Among BWs, all MI
patients had normal glucose tolerance, but 1 of the 25 control subjects
had impaired glucose tolerance (2-hour glucose level of 10.9
mmol/L) (Tables 1
and 2
).
|
|
Basal serum NEFAs were similar among MI patients and control subjects.
Two hours after an oral glucose load, NEFAs were suppressed normally
and completely in PSCs but not in PSMI patients. The two-hour post-OGTT
NEFA level was higher in PSMI patients than in PSCs
(P<.05). Serum NEFA was suppressed normally after the
glucose load in BWCs and BWMI patients (Table 3
).
|
Fasting cholesterol and triglycerides were similar among MI patients and control subjects. Two-hour post-OGTT triglyceride values were similar in PSMI patients than in PSCs but were higher in BWMI patients than in BWCs (P<.05). Fasting insulin was significantly related to fasting triglycerides in whites (MI patients, r=.53, P<.006; control subjects, r=.41, P=.049) but not in Sikhs (MI patients, r=.25, P=.21; control subjects, r=.12, P=.51). As a group, fasting insulin was inversely related to HDL cholesterol in whites (r=-.29, P=.045) but not in Sikhs (r=-.16, P=.26).
Waist-to-hip girth ratio was higher in PSMI patients than in PSCs (P<.05) but similar among white patients and control subjects. There were no differences in physical activity, BMI, blood pressure, or alcohol intake among patients and their respective ethnic control subjects. Sikhs were lifelong nonsmokers, and 16 BWMI patients and 8 BWCs were ex-smokers, having stopped a minimum of 2 months before study. Five BWCs smoked 5 to 15 cigarettes per day.
Family Studies
Fasting plasma insulin, post-OGTT NEFA, and waist-to-hip
girth ratio were similar in PSMI patients compared with their
first-degree relatives. Fasting plasma insulin and waist-to-hip girth
ratio were higher in relatives than in PSCs (both P<.05).
Relatives of PSMI patients had a similar BMI (23±1.7
kg/m2), systolic blood pressure
(123±6.2 mm Hg), leisure-time activity (3.2±0.9 MJ/wk), fasting
glucose (5.6±0.5 mmol/L), 2-hour post-OGTT glucose (7.5±1.2
mmol/L), HDL cholesterol (1.21±0.1 mmol/L), fasting
triglycerides (1.83±0.23 mmol/L) and fasting NEFAs
(0.58±0.7 mEq/L), and lower total cholesterol
(5.2±0.4 mmol/L, P<.05) compared with PSCs (Figure 2
).
|
| Discussion |
|---|
|
|
|---|
Increased abdominal fat is associated with insulin resistance.10 19 20 21 Although the mechanisms linking the two have not been fully elucidated, evidence from previous studies suggests that abdominal visceral fat cells are resistant to the antilipolytic effect of insulin,22 resulting in increased hepatic availability of NEFAs. The latter increases gluconeogenesis,23 reduces hepatic insulin extraction,24 and stimulates VLDL apolipoprotein B and triglyceride production.25 26 Increased NEFAs are also associated with reduced insulin-mediated glucose uptake through the glucosefatty acid cycle,27 leading to glucose intolerance and hyperinsulinemia. In the present study, DXA did not allow quantification of visceral and subcutaneous fat in our patients. Evidence from previous studies has shown that visceral fat is the main depot associated with features of the insulin resistance syndrome.29 The possibility exists therefore that there are differences in the amount of visceral fat among MI patients versus control subjects, and between ethnic groups, which may contribute to the metabolic abnormalities seen in this study.
Impaired insulin-mediated and postglucose load suppression of lipolysis has not been previously reported in MI. However, a direct role for NEFAs in CHD is suggested by the atherogenic and thrombogenic effects of fatty acids28 ; the association of fatty acid concentrations in serum, adipose tissue, and aortic plaque29 ; and the relationship of elevated serum NEFAs with foam cell formation.30 An interrelationship between defective lipolysis and glucose disposal is additionally suggested by studies showing that increased availability of NEFAs impairs insulin-mediated glucose uptake.23 27 31
The contribution of diabetes to impaired insulin action was excluded in the BWMI patients, all of whom had normal glucose tolerance but were insulin resistant compared with BWCs. Sikhs have a 20% prevalence of diabetes.10 32 Five Sikh patients had abnormal glucose tolerance and five had diabetes despite normal fasting blood glucose levels (<6.7 mmol/L) at the time of study. Although abnormal glucose tolerance is likely to have contributed to impaired insulin action in these individuals, the presence of similar defects both in nondiabetic Sikh and white MI patients excludes a major role for diabetes in the development of the aforementioned metabolic abnormalities associated with defective insulin action.
Insulin resistance can be associated with hyperinsulinemia, glucose intolerance, hypertension, hypertriglyceridemia, low HDL cholesterol, small dense LDL, hyperuricemia, and elevated PAI-1.3 33 In this study, insulin was positively correlated with triglycerides and inversely with HDL cholesterol among white subjects. Furthermore, post-OGTT triglycerides, small LDL particle size, and PAI-1 were higher in BWMI patients than in BWCs, and this finding is consistent with previous studies showing a clustering of insulin resistance and metabolic risk factors in CHD.8 However, these patterns were notably absent in Sikhs. Our results imply that in Sikh survivors of premature MI, insulin resistance occurs as a forme fruste, without full expression of the "syndrome" as described by Reaven.3 In Sikhs, the absence of established risk factors for CHD2 and of the metabolic abnormalities usually associated with insulin resistance suggest that defective insulin action per se, defined herein as impaired insulin-mediated glucose uptake, impaired NEFA suppression after oral glucose, and abdominal obesity, is the primary risk factor for premature MI in this ethnic population. Although the possibility cannot be excluded by the present study that these disturbances are a primary consequence of CHD or of lifestyle changes after MI, our results are consistent with previous epidemiological studies that indicate that >70% of major Q-wave abnormalities in Indian Asians, aged 40 to 54 years, are attributable to glucose intolerance and hyperinsulinemia.2
Relatives of PSMI patients were studied to investigate the familial aggregation of insulin resistance. We observed abdominal obesity, impaired NEFA suppression, and hyperinsulinemia in first-degree relatives of Sikh patients with premature MI compared with control subjects. The demonstration of defective insulin action in Sikh CHD families is consistent with family studies in other populations, which indicate that a component of insulin resistance is inherited.34 35 36 A role for poor nutrition in fetal life has recently been proposed by the association of low birth weight with insulin resistance,37 but this does not exclude an important role for genetic factors, which may be amenable to genetic linkage analyses.
In summary, in PS survivors of premature MI, defective insulin action is characterized by impaired insulin-mediated glucose uptake, impaired insulin-mediated NEFA suppression, and abdominal obesity. In BWMI patients, the defects are impaired insulin-mediated glucose uptake and abdominal obesity. Classic coronary risk factors and metabolic features usually associated with insulin resistance, namely, increased post-OGTT triglycerides, smaller LDL particle size, and increased PAI-1, were present in white but not in Sikh MI patients. Abdominal obesity, impaired NEFA suppression, and elevated fasting insulin were also present in asymptomatic, nondiabetic, first-degree relatives of PSMI patients. Our results suggest that these defects may be early metabolic abnormalities in families with premature MI.
| Selected Abbreviations and Acronyms |
|---|
|
| Acknowledgments |
|---|
Received July 23, 1997; accepted December 9, 1997.
| References |
|---|
|
|
|---|
2.
McKeigue PM, Ferrie JE, Pierpoint T, Marmot MG.
Association of early-onset coronary heart disease in South
Asian men with glucose intolerance and
hyperinsulinemia. Circulation. 1993;87:152161.
3. Reaven GM. Banting lecture 1988: role of insulin resistance in human disease. Diabetes. 1988;37:15951607.[Abstract]
4. Reaven GM, Laws A. Insulin resistance, compensatory hyperinsulinaemia, and coronary heart disease. Diabetologia. 1994;37:948952.[Medline] [Order article via Infotrieve]
5. Despres JP, Marette A. Relation of components of insulin resistance syndrome to coronary disease risk. Curr Opin Lipidol. 1994;5:274289.[Medline] [Order article via Infotrieve]
6. Peters N, Hales CN. Plasma insulin concentrations after myocardial infarction. Lancet. 1965;1:11441145.[Medline] [Order article via Infotrieve]
7. Young MH, Jeng CY, Sheu WH, Shieh SM, Fuh MM, Chen YD, Reaven GM. Insulin resistance, glucose intolerance, hyperinsulinemia and dyslipidemia in patients with angiographically demonstrated coronary artery disease. Am J Cardiol. 1994;72:458460.
8. Ferrannini E, Haffner SM, Mitchell BD, Stern MP. Hyperinsulinaemia: the key feature of a cardiovascular and metabolic syndrome. Diabetologia. 1991;34:416422.[Medline] [Order article via Infotrieve]
9. Ferrannini E, Buzzigoli G, Bonadonna R, Giorico MA, Graziadei L, Pedrinelli R, Brandi L, Bevilacqua S. Insulin resistance in essential hypertension. N Engl J Med. 1987;317:350357.[Abstract]
10. McKeigue PM, Shah B, Marmot MG. Relation of central obesity and insulin resistance with high diabetes prevalence and cardiovascular risk in South Asians. Lancet. 1991;337:382386.[Medline] [Order article via Infotrieve]
11. Bhatnagar D, Anand IS, Durrington PN, Patel DJ, Wander GS, Mackness MI, Creed F, Tomenson B, Chandrashekhar Y, Winterbotham M, et al. Coronary risk factors in people from the Indian subcontinent living in West London and their siblings in India. Lancet. 1995;345:405409.[Medline] [Order article via Infotrieve]
12.
Passmore R, Durnin JVGA. Human energy expenditure.
Physiol Rev. 1955;35:801840.
13.
DeFronzo RA, Tobin JD, Andres R. Glucose clamp
technique: a method for quantifying insulin secretion and resistance.
Am J Physiol. 1979;237:E214E223.
14.
Pierson RN Jr, Wang J, Heymsfield SB, Russell-Aulet M,
Mazariegos M, Tierney M, Smith R, Thornton JC, Kehayias J, Weber DA, et
al. Measuring body fat: calibrating the rulers: intermethod comparisons
in 389 normal Caucasian subjects. Am J Physiol. 1991;261:E103E108.
15. Gelding SV, Coldham N, Nithyananthan R, Anyaoku V, Johnston DG. Insulin resistance with respect to lipolysis in non-diabetic relatives of European patients with type 2 diabetes. Diabet Med. 1995;12:6673.[Medline] [Order article via Infotrieve]
16. Meade TW, Howarth DJ, Cooper J, MacCallum PK, Stirling Y. Fibrinolytic activity and arterial disease [letter]. Lancet. 1994;343:1442.
17. Griffin BA, Caslake MJ, Yip B, Tait GW, Packard CJ, Shepherd J. Rapid isolation of low density lipoprotein (LDL) subfractions from plasma by density gradient ultracentrifugation. Atherosclerosis. 1990;83:5967.[Medline] [Order article via Infotrieve]
18. WHO study group. Report on Diabetes Mellitus. Geneva, Switzerland: World Health Organization; technical report series 727. 1985.
19. Pedersen SB, Borglum JD, Schmitz O, Bak JF, Sorensen NS, Richelsen B. Abdominal obesity is associated with insulin resistance and reduced glycogen synthetase activity in skeletal muscle. Metabolism. 1993;42:9981005.[Medline] [Order article via Infotrieve]
20. Despres JP. Abdominal obesity as important component of insulin-resistance syndrome. Nutrition. 1993;9:452459.[Medline] [Order article via Infotrieve]
21. Evans DJ, Murray R, Kissebah AH. Relationship between skeletal muscle insulin resistance, insulin-mediated glucose disposal, and insulin binding: effects of obesity and body fat topography. J Clin Invest. 1984;74:15151525.
22. Bolinder J, Kager L, Ostman J, Arner P. Differences at the receptor and postreceptor levels between human omental and subcutaneous adipose tissue in the action of insulin on lipolysis. Diabetes. 1983;32:117123.[Abstract]
23. Groop LC, Bonadonna RC, DelPrato S, Ratheiser K, Zyck K, Ferrannini E, DeFronzo RA. Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus: evidence for multiple sites of insulin resistance. J Clin Invest. 1989;84:205213.
24.
Kanety H, Moshe S, Shafrir E, Lunenfeld B, Karasik A.
Hyperinsulinemia induces a reversible impairment in
insulin receptor function leading to diabetes in the sand rat model of
non-insulin-dependent diabetes mellitus. Proc Natl Acad Sci
U S A. 1994;91:18531857.
25. Castro Cabezas M, de Bruin TW, de Valk HW, Shoulders CC, Jansen H, Willem Erkelens D. Impaired fatty acid metabolism in familial combined hyperlipidemia: a mechanism associating hepatic apolipoprotein B overproduction and insulin resistance. J Clin Invest. 1993;92:160168.
26.
Aitman TJ, Godsland IF, Farren B, Crook D, Wong HJ,
Scott J. Defects of insulin action on fatty acid and carbohydrate
metabolism in familial combined
hyperlipidemia. Arterioscler Thromb Vasc
Biol. 1997;17:748754.
27. Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose fatty acid cycle: its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet. 1963;1:785789.[Medline] [Order article via Infotrieve]
29. Felton CV, Crook D, Davies MJ, Oliver MF. Dietary polyunsaturated fatty acids and composition of human aortic plaques. Lancet. 1994;344:11951196.[Medline] [Order article via Infotrieve]
30. Laughton CW, Ruddle DL, Bedord CJ, Alderman EL. Sera containing elevated nonesterified fatty acids from patients with angiographically documented coronary atherosclerosis cause marked lipid accumulation in cultured human arterial smooth muscle-derived cells. Atherosclerosis. 1988;70:233246.[Medline] [Order article via Infotrieve]
31. Boden G, Chen X, Ruiz J, White JV, Rossetti L. Mechanisms of fatty acid-induced inhibition of glucose uptake. J Clin Invest. 1994;93:24382446.
32. Mather HM, Keen H. The Southall Diabetes Survey: prevalence of known diabetes in Asians and Europeans. BMJ (Clin Res Ed). 1985;291:10811084.
33. Reaven GM. Role of insulin resistance in human disease (syndrome X): an expanded definition. Annu Rev Med. 1993;44:121131.[Medline] [Order article via Infotrieve]
34. Martin BC, Warram JH, Krolewski AS, Bergman RN, Soeldner JS, Kahn CR. Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study. Lancet. 1992;340:925929.[Medline] [Order article via Infotrieve]
35. Schumacher MC, Hasstedt SJ, Hunt SC, Williams RR, Elbein SC. Major gene effect for insulin levels in familial NIDDM pedigrees. Diabetes. 1992;41:416423.[Abstract]
36. Prochazka M, Lillioja S, Tait JF, Knowler WC, Mott DM, Spraul M, Bennett PH, Bodardus C. Linkage of chromosomal markers on 4q with a putative gene determining maximal insulin action in Pima Indians. Diabetes. 1993;42:514519.[Abstract]
37. Hales CN, Barker DJ. Type 2 (non-insulin-dependent) diabetes mellitus: the thrifty phenotype hypothesis. Diabetologia. 1992;35:595601.[Medline] [Order article via Infotrieve]
This article has been cited by other articles:
![]() |
K. C. Patel, R. Minhas, P. Lincoln, and R. K Dhillon Strategic challenges in the prevention of cardiovascular disease J R Soc Med, March 1, 2008; 101(3): 105 - 107. [Full Text] [PDF] |
||||
![]() |
B. R. Barrows and E. J. Parks Contributions of Different Fatty Acid Sources to Very Low-Density Lipoprotein-Triacylglycerol in the Fasted and Fed States J. Clin. Endocrinol. Metab., April 1, 2006; 91(4): 1446 - 1452. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. T. Timlin, B. R. Barrows, and E. J. Parks Increased Dietary Substrate Delivery Alters Hepatic Fatty Acid Recycling in Healthy Men Diabetes, September 1, 2005; 54(9): 2694 - 2701. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-M. Guettier, A. Georgopoulos, M. Y. Tsai, V. Radha, S. Shanthirani, R. Deepa, M. Gross, G. Rao, and V. Mohan Polymorphisms in the Fatty Acid-Binding Protein 2 and Apolipoprotein C-III Genes Are Associated with the Metabolic Syndrome and Dyslipidemia in a South Indian Population J. Clin. Endocrinol. Metab., March 1, 2005; 90(3): 1705 - 1711. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A Lovegrove, S. S Lovegrove, S. V. Lesauvage, L. M Brady, N. Saini, A. M Minihane, and C. M Williams Moderate fish-oil supplementation reverses low-platelet, long-chain n-3 polyunsaturated fatty acid status and reduces plasma triacylglycerol concentrations in British Indo-Asians Am. J. Clinical Nutrition, June 1, 2004; 79(6): 974 - 982. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. H. Knopp, B. Retzlaff, B. Fish, C. Walden, S. Wallick, M. Anderson, K. Aikawa, and S. E. Kahn Effects of Insulin Resistance and Obesity on Lipoproteins and Sensitivity to Egg Feeding Arterioscler. Thromb. Vasc. Biol., August 1, 2003; 23(8): 1437 - 1443. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. C. Chambers, S. Eda, P. Bassett, Y. Karim, S. G. Thompson, J. R. Gallimore, M. B. Pepys, and J. S. Kooner C-Reactive Protein, Insulin Resistance, Central Obesity, and Coronary Heart Disease Risk in Indian Asians From the United Kingdom Compared With European Whites Circulation, July 10, 2001; 104(2): 145 - 150. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Carlsson, Y. Wessman, P. Almgren, and L. Groop High Levels of Nonesterified Fatty Acids Are Associated With Increased Familial Risk of Cardiovascular Disease Arterioscler. Thromb. Vasc. Biol., June 1, 2000; 20(6): 1588 - 1594. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. R. Kulkarni, J. H. Markovitz, N. C. Nanda, and J. P. Segrest Increased Prevalence of Smaller and Denser LDL Particles in Asian Indians Arterioscler. Thromb. Vasc. Biol., November 1, 1999; 19(11): 2749 - 2755. [Abstract] [Full Text] [PDF] |
||||
![]() |
J C Chambers, A McGregor, J Jean-Marie, and J S Kooner Abnormalities of vascular endothelial function may contribute to increased coronary heart disease risk in UK Indian Asians Heart, May 1, 1999; 81(5): 501 - 504. [Abstract] [Full Text] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1998 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |